SITAgliptin Plus GLARgine to Glycemic Control in the Hospital Setting (SITAGLAR-H)

• Status: Recruiting
• Trial end date: 2024-07-01
• Target enrollment: 0
• Participant gender: All

Summary

In noncritically hospitalized patients, hyperglycemia (defined as blood glucose [BG] levels >140 mg/dL) is a common, serious, and costly healthcare problem. For another hand, the treatment of hyperglycemia is associated with decreased mortality and morbidity. Therefore, clinical guidelines from professional organizations recommend the use of subcutaneous insulin as the preferred therapy in hospitalized patients in a non-intensive care unit setting (target glucose range 100 - 180 mg/dl). The most recommended regimen is basal-bolus insulin therapy, although this regimen requires multiple insulin daily injections and is associated with a significant risk of hypoglycemia (reported in up to 32%). Thus, a simpler regimen that results in similar glycemic efficacy to basal-bolus insulin with less risk of hypoglycemia could improve care for this group of patients.

The basal-plus insulin regimen consists of a single daily dose of basal insulin with supplemental (corrective) doses of rapid-acting insulin analogue before meals. This has similar efficacy and safety as the basal-bolus regimen. However, the basal-plus scheme does not provide prandial coverage of insulin.

In another vein, dipeptidyl peptidase-4 (DPP-4) inhibitors are a class of oral glucose lowering agents that reduce the breakdown of endogenous glucagon-like peptide-1 (GLP-1) stimulating insulin secretion in a glucose-dependent manner. Some clinical trials have demonstrated that DPP-4 inhibitors, in combination with insulin, result in similar improvement in glycemic control and in lower rates of hypoglycemia compared to basal-bolus insulin regimens.

For the above, the use of long-acting insulin analogue with a DPP-4 inhibitor could provide better glycemic control basal and prandial, and this scheme could represent an alternative to the use of a basal-plus regimen alone.

In the present study, the investigators will conduct a prospective randomized clinical trial (RCT) aimed to compare the DPP-4 inhibitor, sitagliptin, in combination with basal-plus insulin therapy and basal-plus insulin scheme alone, in non-critical hospitalized patients.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hospital de Especialidades, Centro Medico Nacional "La Raza", Instituto Mexicano del Seguro Social
• Collaborator: National Polytechnic Institute, Mexico
• Treatments: Sitagliptin Phosphate

Criteria

Inclusion Criteria:

1. Males or female medical non-ICU patients aged between18 - 70 years.

2. A known history of type 2 diabetes > 3 months, receiving either diet alone, oral antidiabetic agents (excluding DPP4 inhibitors) low-dose (≤ 0.5 units/kg/day) insulin therapy.

3. Subjects with BG >180 mg and < 400 mg/dL at the time of randomization without laboratory evidence of diabetic ketoacidosis (serum bicarbonate < 18 mEq/L or positive serum or urinary ketones).

4. Written informed consent.

Exclusion Criteria:

1. Age < 18 or > 70 years.

2. Subjects with increased BG concentration, but without a history of diabetes (stress hyperglycemia).

3. Subjects with a history of type 1 diabetes.

4. Patients with a history of diabetic ketoacidosis or hyperosmolar state.

5. Acute critical illness or coronary artery bypass graft (CABG) surgery is expected to require admission to a critical care unit.

6. Subjects with gastrointestinal obstruction or adynamic ileus or those expected to require gastrointestinal suction.

7. Unable to take oral food or medications.

8. Patients with clinically relevant pancreatic or gallbladder disease.

9. Patients with significant hepatic disease (Child-Pugh score B or C) or impaired renal function (GFR < 50 ml/min).

10. Treatment with oral or injectable corticosteroid.

11. Mental condition rendering the subject unable to understand the nature, scope, and possible consequences of the study.

12. Female subjects are pregnant or breast feeding at time of enrollment into the study.

13. Hypersensitivity to sitagliptin or another contraindication to DPP4 inhibitors.

14. Subject unable to give informed consent.